MorphoSys seeks to proceed to Phase IIa with its lead HuCAL product in RA
This article was originally published in Scrip
Executive Summary
MorphoSys is seeking authorisation to begin a Phase Ib/IIa study in Europe of its lead drug MOR103, a fully human HuCAL-derived monoclonal antibody directed against granulocyte macrophage-colony stimulating factor (GM-CSF), in patients with active rheumatoid arthritis.